EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-2.54%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$969M
AUM Growth
+$969M
(-26%)
Cap. Flow
-$232M
Cap. Flow
% of AUM
-23.92%
Top 10 Holdings %
Top 10 Hldgs %
64.29%
Holding
82
New
14
Increased
14
Reduced
29
Closed
17
Top Buys
| 1 |
HCA Healthcare
HCA
|
$14M |
| 2 |
Bruker
BRKR
|
$13.8M |
| 3 |
Edwards Lifesciences
EW
|
$12.6M |
| 4 |
DexCom
DXCM
|
$11.6M |
| 5 |
Teleflex
TFX
|
$11M |
Top Sells
| 1 |
Insmed
INSM
|
$79.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$49.7M |
| 3 |
United Therapeutics
UTHR
|
$30.8M |
| 4 |
Bio-Techne
TECH
|
$26.2M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$21.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
STAAR Surgical
STAA
$1.36B
| – | – | -91,199 | Closed | -$3.39M |
|
77
Stoke Therapeutics
STOK
$1.08B
| – | – | -52,006 | Closed | -$639K |
|
78
iShares 20+ Year Treasury Bond ETF
TLT
$47.8B
| – | – | 0 | – | – |
|
79
Tourmaline Bio
TRML
$601M
| – | – | -84,380 | Closed | -$2.17M |
|
|
FNA
80
DELISTED
Paragon 28, Inc.
FNA
| – | – | -749,213 | Closed | -$5M |
|
|
NVRO
81
DELISTED
NEVRO CORP.
NVRO
| – | – | -313,780 | Closed | -$1.75M |
|
|
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – | -124,491 | Closed | -$9.11M |
|